Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Jul;7(Suppl 3):S127.
doi: 10.21037/atm.2019.05.72.

Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 ≥50%, but unanswered questions remain

Jose M Pacheco  1 , Dexiang Gao  2 , D Ross Camidge  1
Affiliations
Editorial

Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 ≥50%, but unanswered questions remain

Jose M Pacheco et al. Ann Transl Med. 2019 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: JM Pacheco: Advisory board/consulting for AstraZeneca and Novartis. Honorarium from Genentech and Takeda. Research funding from Pfizer. DR Camidge: Consulting fees from Takeda, Arrys/Kyn, AstraZeneca, Bio-Thera, Celgene, Clovis, Daiichi Sankyo, Genoptix, G1 Therapeutics, Hansoh, Hengrui, Ignyta, Lycera, Mersana Therapeutics, Novartis, Orion, Regeneron, Revolution Medicine and Roche/Genentech. Research funding from Takeda. D Gao has no conflicts of interest to declare.

Comment on

References

    1. Cetin K, Ettinger DS, Hei Y, et al. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. Clin Epidemiol 2011;3:139-48. 10.2147/CLEP.S17191 - DOI - PMC - PubMed
    1. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51. 10.1200/JCO.2007.15.0375 - DOI - PubMed
    1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8. 10.1056/NEJMoa011954 - DOI - PubMed
    1. Pacheco JM, Gao D, Smith D, et al. Natural history and factors associated with overall survival in stage IV ALK rearranged non-small-cell lung cancer. J Thorac Oncol 2019;14:691-700. 10.1016/j.jtho.2018.12.014 - DOI - PMC - PubMed
    1. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018;378:113-25. 10.1056/NEJMoa1713137 - DOI - PubMed